• Conceive and implement strategies to identify biomarkers for clinical programs• Design and manage pharmacodynamics studies on clinical samples• Conceive and supervise preclinical strategies for drugs mechanism of action and combination therapies• Partner with CROs for translational strategies

• Lead in vivo pharmacology preclinical projects from inception through early clinical development• Design immunotherapy-based combination strategies to elicit immune responses and optimize tumor regression in in vivo and in vitro tumor models• Evaluate and optimize efficacy and tolerability of small molecules, immune-based checkpoint inhibitors, chemotherapeutic agents, and cytokines• Manage the research conducted by CROs and interact with external partners• Develop and implement strategies for biomarkers identification using RNA-seq analytical tools• Analyze and interpret complex clinical trials data from blood and tumor samples to assess cytokines, genetic and cellular biomarkers, multi-parameter flow cytometry and immunohistochemistry• Perform pharmacokinetic (PK) data analysis from clinical samples• Maintain experimental records, review, and prepare study reports suitable for regulatory filings and external partners• Prepare peer review manuscripts and posters for immuno-oncology conferences

• Developed in vivo mouse tumor studies for the oncology lead identification program• Designed and executed in vivo strategies to test antibody-based therapies combined with checkpoint inhibitors• Supervised and conducted preclinical procedures performed in murine models, including dosing, cell inoculation, anesthesia, antibody formulation, tumor measurement and dissociation, organ dissection, and cell culture• Supervised and managed the work of research associates• Interpreted, synthesized, and presented results across experiments. Wrote protocols, procedures, and technical reports• Developed scientific and drug-related expertise to optimize treatments and dosing schedules

• Investigated the biological functions of MEF2C and MS4As in the interferon response and calcium signaling by generating Tet-On inducible systems• Performed high throughput transcriptome analysis to study lipids, IFN and LPS inflammatory responses• Mentored and supervised PhD students, interns and lab members

• Discovered the involvement of FBXW7 tumor suppressor in the cellular metabolism of melanoma. Conceived and executed in vitro and in vivo studies• Generated a novel genetically engineered mouse model. Managed in vivo research by performing breeding, tumorigenesis induction, cell inoculation, tumor measurement, biopsies, tissue collection, and analyzed tumor samples through RNA, DNA, protein analysis and microscopy techniques• Investigated the mechanism of action and resistance of several molecular inhibitors utilized in targeted therapies• Performed in-depth studies on molecular signaling pathways in genetically engineered in vivo and in vitro 2D/3D models, generating transient and stable gene knockdown and overexpression through siRNA, shRNA and lentivirus• Examined data generated with high-throughput transcriptome analysis in melanoma cell lines, human primary melanoma, and nevi samples• Wrote manuscripts for publication and performed manuscripts revision. Presented posters at conferences

• Studied the involvement of IGFBP3 in melanoma • Conducted molecular characterization of intracellular signaling pathways by using pharmacological inhibitors • Examined cellular processes by working with human and murine cell cultures

• Characterized the transgenic Arabidopsis 35SIND-P5CS1 inducible by estradiol to study the floral pathways modulated by the proline• Generated engineered modified plant models of Arabidopsis Thaliana with the use of molecular biology techniques• Analyzed the development of roots and the floral apparatus

• Studied the Medulloblastoma Cancer in in vivo mice models with the application of the main molecular biology techniques